All News

Each visit incorporated instruments that included symptom burden, fatigue, anxiety and depression, nutritional risk, and patient activation.

A federal judge heard arguments over whether CMS unlawfully narrowed the Medicaid work requirement exemption for medically frail beneficiaries.

Nearly 60% of medical health plans, 50% of dental health plans, and 25% of providers reported using AI within their workflows in 2025, with use concentrated in administrative functions.

Nitipong Permpalung, MD, MPH, discusses how early remdesivir may reduce graft loss and cardiovascular events after COVID-19 in kidney transplant recipients.

These findings reinforce that matching therapy intensity and type to genetic and treatment-history profile is likely to be the next lever for improving outcomes.

Wildfire smoke from US and Canadian fires is worsening air quality, increasing asthma risks and prompting public health guidance.

A study found that elevated IL-6 and IL-17A levels were associated with greater fatigue for up to 3 years after CRC diagnosis.

In a small, placebo-controlled trial, oral semaglutide reduced heavy drinking days and craving in adults with AUD, though it missed its primary end point.

The FDA's push for faster, more diverse trials misses the real fix: experts say AI simulation and readability, not red tape, close the gap.

Acoramidis attenuated declines in patient-reported health status through 30 months, complementing previously reported survival and hospitalization benefits.

The meta-analysis of 17 studies found that frailty was strongly associated with cognitive impairment in CKD, highlighting the need for further research to determine a causal relationship.

Panel experts at Nashville’s IVBM event discussed matching cancer therapy intensity to disease, easing access barriers, and reforming pharmacy/PBM policies.

Oral zasocitinib delivered skin clearance once limited to injectable biologics in phase 3 psoriasis trials, including hard-to-treat sites.

Everyday discrimination was associated with delayed care, greater emergency department use, and lower preventive care use among US adults.

A target trial emulation found GLP-1 RA initiation was associated with a 21% lower 3-year fragility fracture risk compared with DPP-4 inhibitor therapy.

Shahzad Mian, MD, explains dry eye disease symptoms, key risk factors, and practical management strategies like drops and warm compresses.

This eta-analysis shows sleep variability—not averages—signals psychosis risk, with stage-specific patterns to guide digital biomarkers and care.

Agentic AI can fix behavioral health referral overload by matching patients to the right providers and boosting follow-through, cutting early dropout.

A budget impact model projects that covering delgocitinib cream for moderate to severe chronic hand eczema could save a hypothetical US health plan $87.8 million over 3 years, driven mostly by lower drug costs.

A recent study found semaglutide more than doubled the likelihood of MASH resolution, but it did not significantly improve fibrosis.

A new review argues that bulevirtide is unlikely to succeed as a stand-alone treatment and calls for combination regimens that restore antiviral immunity.

A dermatology review proposes sorting patients with overlapping atopic dermatitis and alopecia areata into 3 immunophenotype-guided archetypes to select and sequence systemic therapy.

Moving to a subQ formulation makes sense, if you want to be 100% convenient for patients and the centers that treat them, explains Xavier Leleu, MD, PhD.

A new analysis finds up to a 98.8% probability that liberal transfusion lowers 30-day death or myocardial infarction risk vs restrictive care.

Closed-loop social care networks move beyond referrals, proving statewide scale can cut ED use and Medicaid costs while tracking real outcomes.

New cancer drugs reached patients fastest, but overall access timelines remained lengthy across the US, France, Germany, and Switzerland.

East Asian patients with generalized myasthenia gravis (gMG) saw meaningful nipocalimab benefits in a Vivacity-MG3 subgroup analysis.

A Lancet Neurology review detailed how Epstein-Barr virus reprograms B cells to trigger multiple sclerosis in genetically susceptible carriers, and outlined the prophylactic vaccines, therapeutic vaccines, antivirals, and T-cell therapies now in clinical testing to interrupt that process.